Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary Fibrosis (NINTECOR)

• ClinicalTrials.gov Identifier: NCT04541680
• Recruitment Status: Recruiting
• First Posted: September 9, 2020
• Last Update Posted: March 2, 2021
• Sponsor: Assistance Publique - Hôpitaux de Paris
• Collaborator: Boehringer Ingelheim
• Information provided by (Responsible Party): Assistance Publique - Hôpitaux de Paris

Study Description

Brief Summary:

Currently, there is no approved treatment for COVID-19 in France, either for the acute phase, nor for the late chronic phase. the investigator suggest that nintedanib has the potential to block the development of lung fibrosis when initiated early enough to inhibit the activation of mesenchymal cells and the progression of virus-induced pulmonary fibrosis. Computerized Tomography (CT) manifestations of fibrosis or fibrous stripes are described in COVID-19 (Ye, Eur Radiol 2020). Pan et al observed fibrous stripes in 17% patients in the early phase of the disease (Pan, Eur Radiol 2020). Ye et al observed bronchiectasis in 2 patients (15.4%) and evidence of pulmonary fibrosis in 3 patients (23.7%) at HRCT performed at 4 weeks (Ye, Eur Radiol 2020). Long term data are still lacking in patients with COVID-19 and the investigators do not know how many patients will have fibrotic sequelae from the acute illness.

Condition or disease	Intervention/treatment	Phase
SARS-Cov-2 Induced Pulmonary Fibrosis	Drug: Nintedanib 150 MG [Ofev]; Other: Placebo	Phase 3

Detailed Description:

At present, investigators have a very limited view on the long-term pulmonary sequelae after COVID-19 pneumonia, particularly in the most severe forms requiring hospitalization. Early thoracic HRCT is a useful tool for the evaluation of patients suspected of COVID-19 pneumonia. Typical features are evocative of the disease in an epidemic context, with multifocal ground-glass opacities, being nodular or not, or crazy-paving with or without consolidations, with a bilateral, peripheral or mixed distribution and involvement of the posterior zones. CT manifestations of fibrosis or fibrous stripes are described in COVID-19. Pan et al observed fibrous stripes in 17% patients in the early phase of the disease. Ye et al observed bronchiectasis in 2 patients (15.4%) and evidence of pulmonary fibrosis in 3 patients (23.7%) at HRCT performed at 4 weeks. Long term data are still lacking in patients with COVID-19 and the investigators do not know how many patients will have fibrotic sequelae from the acute illness.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 250 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Triple (Participant, Care Provider, Investigator)
• Primary Purpose: Treatment
• Official Title: "Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary Fibrosis"
• Actual Study Start Date: October 29, 2020
• Estimated Primary Completion Date: March 2021
• Estimated Study Completion Date: December 2021

Arms and Interventions

Arm	Intervention/treatment
Experimental: Nintedanib; Experimental group will receive nintedanib 150mg BID for 12 months in addition to standard of care (SoC). Nintedanib dose could be reduced to 100mg BID depending on tolerance according to investigator in charge of the patient. The prescription of SoC drugs or procedure will be let to the choice of the investigator in charge of the patient.	Drug: Nintedanib 150 MG [Ofev]; Experimental group will receive nintedanib 150mg BID for 12 months in addition to standard of care (SoC). Nintedanib dose could be reduced to 100mg BID depending on tolerance according to investigator in charge of the patient. The prescription of SoC drugs or procedure will be let to the choice of the investigator in charge of the patient.
Placebo Comparator: Placebo; Control group will receive Placebo BID for 12 months in addition to SoC. The prescription of SoC drugs or procedure will be let to the choice of the investigator in charge of the patient. Standard of care may include pulmonary rehabilitation.	Other: Placebo; Placebo; Other Name: NaCl

Outcome Measures

Primary Outcome Measures :

1. The primary objective is to assess whether nintedanib slows the progression of lung fibrosis in COVID-19 survivors as assessed by the decline in the forced vital capacity (FVC) over 12 months compared to placebo. [ Time Frame: at inclusion and 12 months. ]
   Change in Forced Vital Capacity over 12 months assessed by Annual Rate of Decline in FVC in Overall Population

Secondary Outcome Measures :

1. compare the rate of decline of DLCO over 12 months [ Time Frame: at inclusion, 6 and 12 months ]
   Rate of decline in DLCO estimated by linear regression of DLCO from baseline to 12 months from DLCO measurement at inclusion, 6 and 12 months
2. compare exercise capacity at 12 months [ Time Frame: at 12 months ]
   Absolute change from baseline in the Six-minute walk test (6MWT) at 12 months
3. compare high resolution CT (HRCT) lung opacities extension at 12 months [ Time Frame: at inclusion and 12 months ]
   HRCT fibrosis score and HRCT fibrosis extension (visual and computer-based assessment) at inclusion and 12 months
4. compare change in health-related quality of life [ Time Frame: at 12 months ]
   Absolute change from baseline in the total score on the St. George's Respiratory Questionnaire questionnaire at 12 months
5. compare the evolution of dyspnea over time [ Time Frame: at 3, 6, 9 and 12 months ]
   Absolute change from baseline in the Dyspnea score (Multidimensional Dyspnea Profile and mMRC score) at 3, 6, 9 and 12 months
6. compare change in Depression and anxiety over time [ Time Frame: at 3, 6, 9 and 12 months ]
   The absolute change from baseline Hospital Anxiety and Depression score at 3, 6, 9 and 12 months
7. compare change in lung injury, pulmonary hypertension and inflammation biomarkers [ Time Frame: at inclusion and 12 months ]
   Biomarker assay (KL-6, NT-proBNP, CRP, D-dimers) at inclusion and 12 months
8. pulmonary hypertension prevalence at inclusion and 12 months [ Time Frame: at inclusion and 12 months ]
   Percentage of patients with a tricuspid regurgitation velocity > 2.5, 2.8 and 3.4 m/sec evaluated at baseline and at 12 months.
9. association between genetic susceptibility (MUC5B polymorphism) and lung fibrosis in COVID-19 survivors [ Time Frame: at inclusion ]
   MUC5B at risk allele detection at inclusion
10. safety of nintedanib [ Time Frame: over 12 months ]
    Incidence of clinical or biological adverse events with nintedanib versus placebo over 12 months

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 89 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• History of hospitalization for COVID-19 infection documented with positive PCR or positive serology in the previous 2 to 12 months
• Lung opacities on HRCT involving more than 10% of the lung volume, with fibrotic features
• DLCO≤ 70% of the predicted value

Exclusion Criteria:

• Pre-existing lung disorder with abnormal HRCT (including COPD, lung cancer, or pulmonary fibrosis)
• Laboratory parameter thresholds:
• renal insufficiency with following criteria: Creatinine clearance <30 ml/min estimated by the Cockcroft-Gault equation.
• any of the following liver test criteria above the specified limit: Total bilirubin > 1.5 above the upper limit of the normal range (ULN), except in patients with predominantly unconjugated hyperbilirubinemia (e.g., Gilbert's syndrome). Aspartate or alanine aminotransferase (AST or ALT) >3 × ULN (refer to the protocol, Table 3 p 34 for the management of liver enzyme elevation).
• Recent surgery with wound healing in progress(<7days )
• Patients with underlying chronic liver disease (Child Pugh A, B or C hepatic impairment).

• Significant pulmonary arterial hypertension (PAH) defined by any of the following:

  1. Previous clinical or echocardiographic evidence of significant right heart failure
  2. History of right heart catheterisation showing a cardiac index ≤2 L/min/m²
  3. PAH requiring parenteral therapy with epoprostenol/treprostinil.

• History of cardiovascular diseases, any of the following:

  1. Severe hypertension, uncontrolled under treatment (≥160/100 mmHg), within 6 months of Visit 1
  2. Myocardial infarction within 6 months of Visit 1
  3. Unstable cardiac angina within 6 months of Visit 1.

• Bleeding risk, any of the following:

  1. Known genetic predisposition to bleeding.
  2. Patients who require

  i. Fibrinolysis, full-dose therapeutic anticoagulation (e.g. vitamin K antagonists, direct thrombin inhibitors, heparin, hirudin) ii. High dose antiplatelet therapy.

• Alcohol or drug abuse which in the opinion of the treating physician would interfere with treatment.
• Ongoing or past antifibrotic treatment with pirfenidone or nintedanib
• Hypersensitivity to nintedanib, peanut or soya or to any of the excipients of the specialty Ofev®
• Patients not able to understand and follow study procedures including completion of self-administered questionnaires without help.
• No written informed consent from the patient
• Absence of affiliation to the French social security
• Participation in another interventional research

Contacts and Locations

Contacts

Contact: Bruno Crestani, MD,PHD; 01 40 25 68 00; bruno.crestani@aphp.fr

Locations

France

Pneumologie; Recruiting

Paris, France, 95018

Contact: Crestani Bruno, MD 0140256863 bruno.crestani@aphp.fr

Sponsors and Collaborators

Assistance Publique - Hôpitaux de Paris

Boehringer Ingelheim

More Information

• Responsible Party: Assistance Publique - Hôpitaux de Paris
• ClinicalTrials.gov Identifier: NCT04541680
• Other Study ID Numbers: APHP200527
• First Posted: September 9, 2020
• Last Update Posted: March 2, 2021
• Last Verified: February 2021

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Undecided

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Pulmonary Fibrosis; Fibrosis; Pathologic Processes; Lung Diseases; Respiratory Tract Diseases; Nintedanib; Antineoplastic Agents; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action